AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04687826 — intervention group
Intervention type: OTHER
Intervention: Liberal fluid therapy
Description: Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
Study NCT01860716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
Study NCT01860716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03492879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT Technology
Description: Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
Study NCT01816178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication training
Description: Participants were instructed in the use of a voices output communication aid.
Study NCT01648920 — intervention group
Intervention type: DEVICE
Intervention: NIOX MINO® Instrument (09-1100)
Description: The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
Study NCT01698944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
Study NCT00090870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
Study NCT00090870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
Study NCT00090870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 200mg daily by mouth
Study NCT00613379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: 10 mg/kg PRO 140, one IV dose (N=10)
Study NCT00613379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: 5 mg/kg PRO 140, one IV dose (N=10)
Study NCT00613379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO, one IV dose (N=10)
Study NCT00990509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Study NCT00990509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Study NCT00990509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain MRI with and without contrast
Description: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)
Study NCT00990509 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Brain MRI with and without contrast
Description: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)
Study NCT01639248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: 250 mg per day in oral capsules in 28 day continuous cycles
Study NCT00685867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid molecular MRSA test
Description: PCR-based rapid screening for MRSA carriage
Study NCT00685867 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hand hygiene promotion
Description: * Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~* Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~* Isolation precautions according to the hospitals' capacity and strategy~* Additional basic infection control interventions (if necessary)
Study NCT03608813 — intervention group
Intervention type: OTHER
Intervention: Serum Metabolomics profiling
Description: Untargeted serum metabolomics profiling
Study NCT01078142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus, Rituximab, Bendamustin
Description: Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)
Study NCT01385540 — intervention group
Intervention type: BEHAVIORAL
Intervention: Task-Based Functional Magnetic Resonance Imaging (fMRI)
Description: Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
Study NCT02302040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM2ACT
Description: AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
Study NCT02302040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided
Description: Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
Study NCT01939223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
Study NCT01939223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
Study NCT02666001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT02666001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone
Study NCT02666001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Norbuprenorphine
Description: Buprenorphine and Norbuprenorphine
Study NCT00985972 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical Activity and Nutrition Education
Description: School-based interventions involving Physical Activity or/and Nutrition Education.
Study NCT02497404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible.
Study NCT02497404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
Study NCT02497404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
Study NCT02497404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
Study NCT02497404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
Study NCT01408901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Treadmill Exercise Therapy
Description: Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
Study NCT01408901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Treadmill Exercise Therapy
Description: Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
Study NCT01408901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education sessions (Control)
Description: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
Study NCT01408901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health education sessions (Control)
Description: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
Study NCT01408901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte macrophage colony stimulating factor (GM-CSF)
Description: The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.
Study NCT01408901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granulocyte macrophage colony stimulating factor (GM-CSF)
Description: The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.
Study NCT02308228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
Study NCT02308228 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Resistance Training
Description: Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
Study NCT02308228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be randomized to receive metformin in conjunction with their strength training program.
Study NCT00298883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 360mg PO BID for six weeks
Study NCT02421419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: adreno-cortical steroid anti-inflammatory drug
Study NCT02421419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: a local anesthetic agent
Study NCT02421419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
Study NCT00691288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega Pure followed by placebo
Description: Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
Study NCT00691288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo followed by Omega Pure
Description: Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
Study NCT03382418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp145 C.6980 Vaccine
Description: Administered by intramuscular injection in the deltoid.
Study NCT03382418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.
Study NCT03382418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study NCT04225013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured
Study NCT04225013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
Study NCT03310632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Study NCT01821274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride 2% Cream
Description: 0.2 g applied topically to the infrascapular area of the back.
Study NCT01821274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Study NCT01821274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% solution o sodium lauryl sulfate (SLS)
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
Study NCT01821274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Study NCT04553770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT04553770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04553770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04553770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study NCT04553770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study NCT01038154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
Study NCT03338504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary angiography
Description: Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
Study NCT03338504 — intervention group
Intervention type: RADIATION
Intervention: CT coronary angiography
Description: CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
Study NCT03338504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
Study NCT00000411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive laminectomy
Description: Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
Study NCT00000411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
Study NCT02897466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Antimicrobial Susceptibility Testing
Description: An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
Study NCT02432209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
Study NCT02432209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.